Apr 23 2009
NanoBio Corp. announced today that it will present compelling new data highlighting key milestones in the development of its novel non-inflammatory nanoemulsion adjuvant platform technology at the National Foundation for Infectious Diseases (NFID) conference, April 27-29. The new data will be delivered in two presentations during the 12th Annual Conference on Vaccine Research in Baltimore, Maryland.
Following is the data presentation schedule:
Monday, April 27, 2009
Poster Presentation: #166, 10:00 AM - 11:30 AM
Nasal Administration of Nanoemulsion W80/5EC Adjuvanted Influenza Vaccine in Mice
Oral Presentation: #165, 3:30 PM - 5:00 PM
W80/5EC, A Nanoemulsion Adjuvant Provides Robust Anti-influenza Immunity in
Ferrets after a Single Immunization
NanoBio’s nanoemulsion-based, intranasal vaccines have elicited robust immune responses in animals vaccinated against influenza, hepatitis B, RSV, HIV, cancer, anthrax, smallpox and other diseases. The NanoStat™ platform technology has demonstrated numerous potential advantages over traditional vaccines, including: the ability to generate robust mucosal, systemic and cellular immunity; antigen-sparing qualities; cross-protection against non-vaccinated strains; ability to adjuvant multiple antigen types without inducing inflammation; thermally stabilizing the vaccine; and removing the need for needles.
NanoBio Corp. announced earlier this week that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application for the Phase 1 clinical study of NB-1008, a seasonal influenza vaccine administered via a nasal dropper. In numerous animal studies, NB-1008 has demonstrated robust mucosal, systemic and cellular immunity without inflammation or safety concerns.